

ASX ANNOUNCEMENT

2 February 2026

Biome Expands Canadian Practitioner Channel with Fullscript Distribution Partnership

- All Biome Activated Probiotics products approved for launch on Fullscript Canada platform with launch planned for February 2026
- Fullscript serves over 100,000 healthcare practitioners and 5 million patients across North America
- Partnership complements existing Ecotrend Ecologics relationship to deliver complete Canadian market coverage

Microbiome health company Biome Australia Limited (ASX: BIO) ('Biome' or 'the Company') is pleased to announce it has secured distribution for its entire Canadian range on Fullscript, North America's dominant practitioner distribution platform, and agreed on commercial terms.

Strategic significance

The Fullscript partnership represents a significant milestone in Biome's Canadian expansion, providing access to the dominant platform for practitioner-to-patient supplement dispensing across the region. The North American integrative medicine market has grown at a 25% CAGR, with approximately 80% of healthcare professionals now recommending supplements in some capacity.¹

Canada's practitioner channel is anchored by Naturopathic Doctors (NDs), a rigorous four-year postgraduate medical qualification that positions these practitioners as trusted authorities in integrative health. Health Canada's stringent regulatory framework for

¹ Grand View Research, Complementary and Alternative Medicine Market Report, 2024

natural health products creates a significant barrier to entry, favouring established, compliant brands like Activated Probiotics.

Complete Canadian Practitioner Market Coverage

The Fullscript partnership is strategically complementary to Biome's existing partnership with Ecotrend Ecologics, one of Canada's leading natural health products distributors with over 30 years of industry expertise. Together, these partnerships deliver comprehensive coverage of the Canadian practitioner market across both traditional wholesale distribution (Ecotrend) and direct-to-patient digital dispensing (Fullscript).

This dual-channel approach ensures Biome's Activated Probiotics range is accessible to practitioners regardless of their preferred dispensing model, whether maintaining in-clinic inventory through wholesale ordering or utilising Fullscript's innovative e-prescribing platform that ships products directly to patients' homes.

Management commentary

Blair Norfolk, CEO and Managing Director of Biome Australia, commented:

"Securing approval on Fullscript is a pivotal milestone in our Canadian expansion. Combined with our existing Ecotrend partnership, we now have complete coverage of the Canadian practitioner market, traditional wholesale through Ecotrend for in-clinic dispensaries, and digital direct-to-patient through Fullscript. This dual-channel approach removes any barriers to practitioners choosing Activated Probiotics for their patients."

"This partnership demonstrates continued momentum in our Vision 27 international expansion strategy. We're systematically building scale across key markets, Canada, Ireland, New Zealand and the UK—establishing Biome as a truly global leader in evidence-based microbiome health. Fullscript's broader platform reach positions us well for ongoing growth opportunities."

—ENDS—

This announcement has been authorised for release by the Board of Biome Australia Limited.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines supported by clinical research. Biome aims to improve health outcomes and quality of life, making products accessible through professional health channels.

Incorporated in Australia in 2018, Biome distributes locally and internationally. In partnership with leading microbiome research organizations, Biome produces unique live biotherapeutic products with innovative delivery technologies improving stability and efficacy for its flagship Activated Probiotics® range.

Supported by randomized double-blind placebo-controlled clinical trials, Activated Probiotics® and Activated Therapeutics® help prevent and support management of various health concerns including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-recommended distribution, Biome educates health professionals on gut microbiota's systemic health effects, providing evidence-based natural medicines for prevalent chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations
Lauren Dwyer
corporate@biomeaustralia.com

Media enquiries
media@activated.co

Forward Looking Statements

This release contains forward looking statements, including projections, guidance on future revenues, earnings and estimates regarding Biome's future performance (Forward Looking Statements). Forward Looking Statements are provided as general guidance only and should not be relied upon as indication or guarantee of future performance.

Actual results, performance or achievements may differ materially from those expressed or implied in Forward Looking Statements. Such statements assume success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to accuracy, likelihood of achievement or reasonableness of Forward Looking Statements contained in this release. Except as required by law or regulation (including ASX Listing Rules), Biome does not undertake to provide additional or updated information whether as result of changed expectations, new information, future events or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to fairness, currency, accuracy, reliability or completeness of information in this release or accuracy, likelihood of achievement or reasonableness of Forward Looking Statements contained in, implied by, or part of this release, or that this release contains all material information about Biome which prospective investors may require in evaluating possible investment in Biome.